Analysis – Page 138 – Goldea Capital

Mint’s New JV Rice Robotics AGI Integrates Fan-Favorite B.Duck IP for Companion Robot Debut at Licensing Expo Las Vegas

Written by Customer Service on May 28, 2026. Posted in Public Companies.

Hong Kong, May 28, 2026 (GLOBE NEWSWIRE) — Mint Incorporation Limited (“Mint” or the “Company”, together with its subsidiaries, the “Group”, NASDAQ: MIMI), a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced a major step forward in its robotics business expansion. Following the successful delivery of FLOKI Minibot M1, the Group has established a new joint venture with Rice Robotics Holdings Limited (“Rice Robotics”) — Rice Robotics AGI Holding Limited (“Rice Robotics AGI”). The joint venture has signed a non-binding Memorandum of Understanding (“MOU”) with certain subsidiaries of B.Duck Semk Holdings International Limited (“B.Duck Semk”, together with its subsidiaries, the “B.Duck Group”, HKEX: 2250),...

Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis – Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation

Written by Customer Service on May 28, 2026. Posted in Public Companies.

TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide pipeline have been accepted for presentation at ENDO 2026, the annual meeting of the Endocrine Society, taking place June 13-16, 2026 in Chicago, Illinois, USA. Notably, new clinical data supporting Entera’s single EB613 tablet as the final candidate for its planned Phase 3 study in postmenopausal women with osteoporosis was selected for a Late Breaking Oral Presentation. Abstract Title: Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 StudySession Title: Late-Breaking Oral Abstract/Rapid-Fire IISession Date/Time: Sunday,...

Mint and Rice Robotics Launch Joint Venture to Expand AI Companion Robot Business with HK$15M in funding

Written by Customer Service on May 28, 2026. Posted in Public Companies.

Hong Kong, May 28, 2026 (GLOBE NEWSWIRE) — Mint Incorporation Limited (“Mint” or the “Company”, together with its subsidiaries, the “Group”, NASDAQ: MIMI), a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced that on May 22, 2026, its wholly-owned subsidiary, Aspiration X Limited (“Aspiration X”), has entered into a joint venture agreement (the “JV Agreement”) with Rice Robotics Holdings Limited (“Rice Robotics”) to establish Rice Robotics AGI Holding Limited (“Rice Robotics AGI”), a new British Virgin Islands joint venture company. Rice Robotics AGI will focus on the development and sales of the next generation of AI companion robots, or as may be expanded or changed by Rice Robotics AGI from time...

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

Written by Customer Service on May 28, 2026. Posted in Public Companies.

TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange (“TSX”) for the acquisition of approximately 54% interest in CliniQuantum Ltd. (“CliniQuantum”) (the Transaction”). As previously disclosed, in March 2026, NeuroThera, CliniQuantum and the certain shareholders of CliniQuantum, (the “Selling Shareholders”) entered into a share purchase agreement (the “SPA”), pursuant to which, NeuroThera will acquire 56,375 ordinary shares of CliniQuatum, representing approximately 54% of the issued and outstanding...

Aduro Clean Technologies to Participate in Industry and Investor Conferences in June 2026

Written by Customer Service on May 28, 2026. Posted in Public Companies.

LONDON, Ontario, May 28, 2026 (GLOBE NEWSWIRE) — Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (TSX: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, announces its participation in several industry and investor conferences in June 2026. The program includes one-on-one institutional investor meetings in London UK, a Toronto Stock Exchange-hosted investor event in Canada, and two technical conferences. Conference and Trade Program Highlights:One-on-one institutional investor meetings at the 16th Annual ROTH London Conference, with CEO Ofer Vicus and CFO Mena Beshay representing Aduro, continuing engagement with international institutional investors following...

Diana Shipping Inc. Reports Financial Results for the First Quarter Ended March 31, 2026; Declares Cash Dividend of $0.01 Per Common Share

Written by Customer Service on May 28, 2026. Posted in Earnings Releases And Operating Results.

ATHENS, Greece, May 28, 2026 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today reported net income of $29.1 million and net income attributed to common stockholders of $27.7 million for the first quarter of 2026. This compares to net income of $3.0 million and net income attributable to common stockholders of $1.6 million for the first quarter of 2025. Earnings per share for the first quarter of 2026 was $0.25 basic and diluted, compared to $0.01 basic and diluted for the same quarter of 2025. Time charter revenues were $54.7 million for the first quarter of 2026, compared to $54.9 million for the same quarter of 2025. The slight decrease in time charter revenues, compared to the same quarter of the prior...

PureCycle Achieves ISO 9001:2015 Certification, Demonstrating Operational Maturity and Customer Readiness at Scale

Written by Customer Service on May 28, 2026. Posted in Public Companies.

Independent Quality Management Certification Reinforces PureCycle’s Commitment to Consistent, Auditable Production of Recycled Polypropylene ORLANDO, Fla., May 28, 2026 (GLOBE NEWSWIRE) — PureCycle Technologies, Inc. (Nasdaq: PCT), a U.S.-based company revolutionizing plastic recycling, today announced it has achieved ISO 9001:2015 certification from DQS Global, an accredited third-party certification organization. The certification covers PureCycle’s Quality Management System (QMS) across the entirety of its Ironton, Ohio dissolution recycling facility. ISO 9001:2015 is the world’s most widely adopted quality management standard, with more than one million certified organizations globally. Certification requires an independent audit confirming that an organization has implemented documented, repeatable processes; a...

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Written by Customer Service on May 28, 2026. Posted in Public Companies.

WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday June 4, 2026, at 2:00 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference in New York, NY. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to...

CECO Environmental and Thermon Group Holdings Announce that their respective Stockholders Approved the Strategic Combination and Provide Update on Election Results

Written by Customer Service on May 28, 2026. Posted in Mergers And Acquisitions.

ADDISON, Texas and AUSTIN, Texas, May 28, 2026 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) (“CECO”) and Thermon Group Holdings, Inc. (NYSE: THR) (“Thermon”) announced that both companies’ stockholders overwhelmingly voted to approve the previously announced strategic combination at their respective stockholder meetings held earlier today. Preliminary results showed that approximately 99.93% of votes cast at CECO’s annual meeting were voted in favor of the transaction, and nearly 99.97% of the votes cast at Thermon’s meeting were in support of the combination. The final voting results will be reported in each of the company’s respective Form 8-K filings with the U.S. Securities and Exchange Commission. “We appreciate the strong support from both companies’ stockholders and remain excited about bringing together complementary...

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Written by Customer Service on May 28, 2026. Posted in Earnings Releases And Operating Results.

Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044 Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist investors Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in the fourth quarter of 2026 Sol-Gel signed an exclusive license agreement with Sun Pharmaceutical Industries Ltd. for the commercialization of TWYNEO® in IndiaNESS ZIONA, Israel, May 28, 2026 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals